Pan-cancer landscape of tumour endothelial cells pinpoints insulin receptor as a novel antiangiogenic target and predicts immunotherapy response

Clin Transl Med. 2023 Dec;13(12):e1501. doi: 10.1002/ctm2.1501.

Authors

Yongqiang Zheng¹, Yi-Qian Pan¹, Kun Liao¹, Kai Yu¹, Qinian Wu¹, Yanxing Chen¹, Yuqing Deng¹, Hui Sun¹, Hengying Pu¹, Huai-Qiang Ju¹, Rui-Hua Xu^{1

2}, Ze-Xian Liu¹

Affiliations

¹ Department of Medical Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Guangzhou, P. R. China.
² Research Unit of Precision Diagnosis and Treatment for Gastrointestinal Cancer, Chinese Academy of Medical Sciences, Guangzhou, P. R. China.

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Angiogenesis Inhibitors / pharmacology
Angiogenesis Inhibitors / therapeutic use
Endothelial Cells*
Humans
Immunotherapy
Neoplasms* / drug therapy
Receptor, Insulin

Substances

Receptor, Insulin
Angiogenesis Inhibitors

Grants and funding